Recommendations for patient screening in ultra-rare inherited metabolic diseases: what have we learned from Niemann-Pick disease type C?

Abstract

BackgroundRare and ultra-rare diseases (URDs) are often chronic and life-threatening conditions that have a profound impact on sufferers and their families, but many are notoriously difficult to detect. Niemann-Pick disease type C (NP-C) serves to illustrate the challenges, benefits and pitfalls associated with screening for ultra-rare inborn errors of metabolism (IEMs).A comprehensive, non-systematic review of published information from NP-C screening studies was conducted, focusing on diagnostic methods and study designs that have been employed to date. As a key part of this analysis, data from both successful studies (where cases were positively identified) and unsuccessful studies (where the chosen approach failed to identify any cases) were included alongside information from our own experiences gained from the planning and execution of screening for NP-C. On this basis, best-practice recommendations for ultra-rare IEM screening are provided. Twenty-six published screening studies were identified and categorised according to study design into four groups: 1) prospective patient cohort and family-based secondary screenings (18 studies); 2) analyses of archived ‘biobank’ materials (one study); 3) medical chart review and bioinformatics data mining (five studies); and 4) newborn screening (two studies). NPC1/NPC2 sequencing was the most common primary screening method (Sanger sequencing in eight studies and next-generation sequencing [gene panel or exome sequencing] in five studies), followed by biomarker analyses (usually oxysterols) and clinical surveillance.ConclusionsHistorically, screening for NP-C has been based on single-patient studies, small case series, and targeted cohorts, but the emergence of new diagnostic methods over the last 5–10 years has provided opportunities to screen for NP-C on a larger scale. Combining clinical, biomarker and genetic diagnostic methods represents the most effective way to identify NP-C cases, while reducing the likelihood of misdiagnosis. Our recommendations are intended as a guide for planning screening protocols for ultra-rare IEMs in general.Electronic supplementary materialThe online version of this article (10.1186/s13023-018-0985-1) contains supplementary material, which is available to authorized users.

Hereditary Hypofibrinogenemia with Hepatic Storage

“…Again, we were not able to find any nucleotide variation corresponding to the already reported HHHS-causing mutations. Even taking into account that we focused only on the already known genetic defects and that we could have missed so-far undisclosed mutations, our exploration of publicly available databases strongly suggests that HHHS is an ultra-rare disease (in the EU, an ultra-rare disorder is defined as affecting < 2:100,000 people [ 52 ]).…”

Identification of novel mutations among Iranian NPC1 patients: a bioinformatics approach to predict pathogenic mutations

“…Niemann-Pick type C (NPC) disease, is a rare genetic and neurodegenerative disorder induced by intracellular accumulation of free cholesterol and gangliosides into lysosomes or late endosome systems [ 1 ]. The NPC was estimated to affect at least one person per 100,000 individuals [ 2 , 3 ]. Of note, the patients affected by this disease are clinically heterogeneous with a broad spectrum of phenotypes and age of onset is variable.…”

Gene Therapy in a Mouse Model of Niemann–Pick Disease Type C1

“…6 Although NPC1 is a systemic progressive disease, the main symptoms are related to the dysfunction of the CNS and liver. 7 Characteristic neurological symptoms are severe developmental delay, especially in early infantile type, and deterioration with vertical supranuclear gaze palsy and cataplexy in the late infantile to adult types. Other symptoms include hypotonia, cerebellar ataxia, dystonia, epileptic seizures, and psychiatric problems.…”